Medtronic plc
Medtronic
Medtronic plc is the world's largest standalone medical device company, founded in 1949 in Dublin, Ireland. With annual revenue of $34.76 billion in fiscal 2025, the company operates 80+ manufacturing and R&D sites across the globe, employing more than 95,000 people. Medtronic is a dominant force in home medical devices, particularly through its diabetes division that generates over $2.76 billion in annual revenue from insulin pump systems and continuous glucose monitoring integration. The company's MiniMed line of insulin pumps represents the gold standard in automated insulin delivery, featuring advanced hybrid closed-loop algorithms that integrate with CGM sensors.
Strengths: Unmatched scale as the world's largest pure-play medical device company with deep R&D capabilities. Leading position in diabetes home care with the MiniMed product ecosystem. Strong regulatory expertise across FDA, CE, and global markets. Robust supply chain with manufacturing redundancy across North America, Europe, and Asia. Revenue growth acceleration with 10+ quarters of enterprise growth momentum.
Weaknesses: Diabetes division subject to intense competition from Dexcom and Insulet in the CGM and patch pump segments. Recent spin-off evaluation for diabetes business creates organizational uncertainty. Legacy product lines in cardiac and surgical segments face margin pressure from newer entrants.Read MoreShow Less
Strengths: Unmatched scale as the world's largest pure-play medical device company with deep R&D capabilities. Leading position in diabetes home care with the MiniMed product ecosystem. Strong regulatory expertise across FDA, CE, and global markets. Robust supply chain with manufacturing redundancy across North America, Europe, and Asia. Revenue growth acceleration with 10+ quarters of enterprise growth momentum.
Weaknesses: Diabetes division subject to intense competition from Dexcom and Insulet in the CGM and patch pump segments. Recent spin-off evaluation for diabetes business creates organizational uncertainty. Legacy product lines in cardiac and surgical segments face margin pressure from newer entrants.
Listed market data
MDT · NYSE · weeklyHistory →- Market cap
- $121 B
- Share price
- USD 94.75
- 1Y change
- -1.1%
- Recent change
- -1.2%
- Since first close
- ×271
- Revenue (TTM)
- $37.5 B
10-22 → 10-23
from 1973-05
Financial history
Full market history- 2026-10USD 94.75$121 B+9.8%
- 2026-09USD 86.29$110 B-4.8%
- 2026-08USD 90.65$115 B+6.2%
- 2026-07USD 85.39$108 B+9.2%
- 2026-06USD 78.23$99.4 B+6.0%
- 2026-05USD 73.81$93.8 B-8.8%
- 2026-04USD 80.97$103 B-6.6%
- 2026-03USD 86.65$110 B-11.3%
- 2026-02USD 97.66$124 B-5.1%
- 2026-01USD 102.96$131 B+7.2%
- 2025-12USD 96.06$122 B-8.8%
- 2025-11USD 105.33$134 B—
In the press
All coverage →5 latest headlines1- 8th Circ. Panel Doubts Investors' Medtronic Insulin Pump Suit - Law360www.law360.com2026-10-20
- Medtronic gains CE mark for next-gen portfolio of conduction system pacemakers - Cardiovascular Businesscardiovascularbusiness.com2026-10-20
- Medtronic PLC stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatchwww.marketwatch.com2026-10-20
- Medtronic’s next-gen pacemaker portfolio secures CE mark - Medical Device Networkwww.medicaldevice-network.com2026-10-20
- Medtronic wins CE mark for Vitalis portfolio of cardiac pacemakers - MedTech Divewww.medtechdive.com2026-10-20
• MiniMed 780G with SmartGuard hybrid closed-loop technology for automated insulin delivery
• Smart MDI multiple daily injections system with InPen smart insulin pen
• Guardian 4 continuous glucose monitoring CGM sensor with real-time glucose readings
• CareLink personal diabetes management software platform with cloud connectivity
Cardiac & Vascular – Implantable Cardiac Devices
• Micra leadless pacemaker, the world's smallest implanted pacemaker
• Resolute Onyx drug-eluting coronary stent system
• Arctic Front Advance cryoablation catheter for atrial fibrillation treatment
• Reveal LINQ insertable cardiac monitor for long-term heart rhythm surveillance
Neuromodulation – Pain Management & Movement Disorders
• Percept PC deep brain stimulation system for Parkinson's disease
• Intellis platform for chronic pain management with adaptive stimulation
• InterStim sacral neuromodulation for bladder and bowel control
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2026 | $36.4 B | $4.8 B |
| 2025 | $33.5 B | $4.7 B |
| 2024 | $32.4 B | $3.7 B |
| 2023 | $31.2 B | $3.8 B |
| 2022 | $31.7 B | $5 B |
Annual results from company filings (SEC XBRL), converted to US dollars.
Quick Facts
Headquarters
Dublin, Ireland
Founded
1949
Employees
95000
Revenue
34760000000
Market cap
$121 B
Factories
80+ manufacturing and R&D sites globally across US, Ireland, Puerto Rico, Singapore
Presence
Global operations in 150+ countries
Listing
NYSE: MDTCategories
Related
Similar listed companies
- Eli Lilly and Company· $1.1 T
- Johnson & Johnson (J&J)· $616 B
- Allergan Aesthetics· $504 B
- AbbVie Inc.· $504 B
- F. Hoffmann-La Roche AG· $372 B
- Merck Animal Health· $360 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website NYSE: MDT , Data Sources & Methodology
Medtronic Official Website
Medtronic - Wikipedia
Medtronic Revenue - Macrotrends
Medtronic Q3 Fiscal 2026 Results
Medtronic Diabetes Spin-off - MedTech Dive